Insights into a Possible Mechanism Underlying the Connection of Carbendazim-Induced Lipid Metabolism Disorder and Gut Microbiota Dysbiosis in Mice

Posted by: | December 14, 2023 | Comments


Carbendazim (CBZ), a systemic, broad-spectrum benzimidazole fungicide, is widely used to control fungal diseases and has been regarded as an endocrine disruptor that causes mammalian toxicity in different target organs. Here, we discovered that chronic administrations of CBZ at 0.2, 1, and 5 mg/kg body weight for 14 weeks not only changed the composition of gut microbiota but also induced significant increases in body, liver, and epididymal fat weight in mice. At the biochemical level, the serum triglyceride (TG) and glucose levels also increased after CBZ exposure. Moreover, the level of serum lipoprotein lipase (LPL), which plays an important role in fatty acid release from TG, was decreased significantly. For gut microbiota, 16S rRNA gene sequencing and real-time qPCR revealed that CBZ exposure significantly perturbed the mice gut microbiome, and gas chromatography found that the production of short-chain fatty acids were altered.

Read more at: Toxicological Sciences

Cuiyuan Jin, Zhaoyang Zeng, Caiyun Wang, Ting Luo, Siyu Wang, Jicong Zhou, Yingchun Ni, Zhengwei Fu, and Yuanxiang Jin. Toxicological Sciences. DOI: 24 August 2023.

Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy

Terms & Conditions | Privacy Policy | © 2021 The Translational Microbiome Research Forum

As of 3/31 the forum will no longer be active. Please visit for future bioscience events as Taconic remains committed to leading the industry in microbiome solutions. Thank you for your support.